Precision BioSciences, Inc.
302 East Pettigrew Street
About Precision BioSciences, Inc.
Precision BioSciences, Inc. (Nasdaq: DTIL) is a clinical stage gene editing company developing in vivo gene editing and ex vivo allogeneic CAR T therapies with its highly precise and versatile ARCUS genome editing platform. ARCUS uses sequence-specific DNA-cutting enzymes, or nucleases designed for gene knock out, as well as highly sophisticated edits for gene insertion and/or gene repair. Precision’s in vivo gene editing pipeline consists of wholly-owned preclinical candidates for primary hyperoxaluria type 1 (PBGENE-PH1), familial hypercholesteremia (PBGENE-PCSK9) and chronic hepatitis B (PBGENE-HBV). It has also partnered with Lilly to develop candidates for Duchenne muscular dystrophy and two other programs targeting the liver and CNS. Precision’s allogeneic CAR T pipeline consists of multiple investigational candidates in early-stage clinical trials, including its first and second generation CD19 targeting candidates PBCAR0191 and PBCAR19B for relapsed and/or refractory (R/R) non-Hodgkin and B-cell lymphoma patients. Precision has also prioritized development of PBCAR269A, its BCMA targeted candidate in combination with a gamma secretase inhibitor for R/R patients with multiple myeloma. Precision BioSciences and its in-house manufacturing facility for AAV, mRNA, and CAR T cells is based in Durham, North Carolina. For more information about Precision BioSciences please visit www.precisionbiosciences.com
Stock Symbol: DTIL
Stock Exchange: NASDAQ
Precision BioSciences: Culture
238 articles about Precision BioSciences, Inc.
Precision BioSciences Announces that the US Patent Office Issues Final Decisions Rejecting Claims of Four Cellectis Patents
Precision BioSciences Announces that the US Patent Office Action Issues Second Actions Rejecting All Claims Asserted by CELLECTIS SA in Litigation
Precision BioSciences Announces Successful Collaboration Results and Extension of Partnership with Bayer CropScience AG
Precision BioSciences Announces that the European Patent Office Issues Written Decision Confirming CELLECTIS SA's Loss of Patent Protection for Single-Chain Meganucleases in Europe
Precision BioSciences Announces that the US Patent Office Issues Second Actions Rejecting Previously Granted Claims to CELLECTIS SA's Core Technology
Precision BioSciences Announces that CELLECTIS SA Loses Patent Protection for Single-Chain Meganucleases in Europe
Cellectis BioResearch European Patent EP 1 485 475 upheld against Precision BioSciences at European Patent Office
Precision BioSciences Announces U.S. Patent Office Reexamination of CELLECTIS SA Patents Involved in Litigation
Precision BioSciences Announces U.S. Patent Office Reexamination of Cellectis Patents Involved in Litigation
Bayer CropScience AG and Precision BioSciences Collaborate to Create Site-Specific Genome Modifications in Plants
Precision BioSciences Issues Update Regarding Recent U.S. Patent Office Action Concerning CELLECTIS SA's Patents
Precision BioSciences Release: US Patent Office Action Rejects Key Claims to CELLECTIS SA' Core Technology
CELLECTIS SA Sues Precision BioSciences for Infringement of Its Patents Concerning Meganuclease Technology